Drug profile · INN
bendroflumethiazide
NADOLOL AND BENDROFLUMETHIAZIDE
bendroflumethiazide (NADOLOL AND BENDROFLUMETHIAZIDE) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bendroflumethiazide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bendroflumethiazide (NADOLOL AND BENDROFLUMETHIAZIDE) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Thiazide-sensitive sodium-chloride cotransporter inhibitor
Primary target: Solute carrier family 12 member 3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bendroflumethiazide?
bendroflumethiazide (NADOLOL AND BENDROFLUMETHIAZIDE) is a thiazide-sensitive sodium-chloride cotransporter inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bendroflumethiazide?
NADOLOL AND BENDROFLUMETHIAZIDE is a marketed brand name for bendroflumethiazide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bendroflumethiazide?
bendroflumethiazide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.